Sex-aware prescribing is a practical and necessary step toward equitable care. Key obstacles include historical underrepresentation of women in trials and insufficient sex-disaggregated data. We advocate for powering future trials for sex-specific analyses, updating clinical guidelines, and using decision support tools for dose adjustments. Integrating a gender lens into all levels of antimicrobial stewardship is essential to move from simply describing disparities to actively closing them.
Colpani et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: